LTR Pharma Logo

LTR Pharma

LTR Pharma is a Clinical Stage Biopharmaceutical Company

SPONTAN® (SDS-089) is a novel intranasal drug (PDE5) delivery platform for Erectile Dysfunction

About Erectile Dysfunction

Erectile Dysfunction (ED) is a condition in which you are unable to get or keep an erection firm enough for satisfactory sexual intercourse. ED can be a short-term or long-term problem.

Our Solution

SPONTAN® provides on demand delivery and faster effect. A lower dose provides less systematic exposure and reduced side effects

Commercialisation

LTR Pharma is commercialising a ‘First in Class’ rapid treatment for Erectile Dysfunction (ED) SPONTAN® with fast-track US NDA Filing within two years

322M

worldwide expected cases by 2025

10

minute effectiveness

$7.10B

projected global market value 2024

Global Market Need

ED is a serious and common medical problem with significant impacts to both physical and psychological health
ED has been identified as a major factor in relationship breakdown (20%). The worldwide prevalence doubled in the last 30 years and is expected to increase to 322 million in 2025.

ON DEMAND
SOLUTION

LTR Pharma Couple

RAPID ONSET
ACTION

BRING BACK
SPONTANEITY

Conversation Series | Innovations in Treatments for ED with Dr. Tom Silva

In the latest video from our Conversation Series, specialist GP Dr. Tom Silva discusses crucial considerations in clinical practice with regards to ED treatment selection and patient care. Dr. Silva explores how common side effects and delayed action can impact patient confidence, while highlighting how rapid-acting treatments, like SPONTAN, can

Read More »

Quarterly Activities Report and 4C

LTR Pharma has today released its Quarterly Activities Report and Appendix 4C Quarterly Cash Flow report for the quarter ended 31 December 2024. Key highlights from this period include: Breakthrough Final Clinical Data: SPONTAN® achieves 470% faster absorption than oral PDE5 tablets showing it can be effective within 10 minutes

Read More »

LTR Pharma Signs National Pharmacy Distribution Agreement with Symbion   

LTR Pharma is pleased to announce it has entered into an agreement with Symbion Pty Ltd, a leading pharmaceutical wholesaler in Australia, to establish national distribution capabilities for SPONTAN®. Under the agreement, Symbion will provide warehousing, inventory management and nationwide distribution services for SPONTAN through its extensive network of distribution

Read More »

Special Access Scheme

SPONTAN may be prescribed to eligible patients under the TGA’s Special Access Scheme. For more information, please register your details via our online form.

Receive our latest news and investor updates

By entering your email address you are agreeing to our privacy policy.